Key clinical point: Radium-223 in combination with enzalutamide is safe in the long term and improves second-line prostate-specific antigen (PSA)-progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) vs. enzalutamide alone.
Major finding: Median follow-up was 22 months. Radium-223 plus enzalutamide vs. enzalutamide alone did not improve median overall survival ( P = .73), PSA-PFS ( P = .97), and radiographic PFS ( P= .96). Radium-223 plus enzalutamide vs enzalutamide alone significantly improved second-line PSA-PFS (18.7 months vs 8.41 months; P = .033).
Study details: A phase 2 randomized trial of 47 patients with mCRPC randomly assigned to receive either radium-223 dichloride with enzalutamide or enzalutamide alone.
Disclosures: The study was supported by the University of Utah. The authors did not disclose any conflict of interests.
Source: Maughan BL et al. Oncologist. 2021 Aug 22. doi: 10.1002/onco.13949 .